Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system
Author:
- 1 November 2007
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 24 (6) , 1290-1304
Abstract
Many factors contribute to the overall risk of cardiovascular disease (CVD) in a given patient. Activation of the renin-angiotensin-aldosterone system (RAAS) is pivotal in the pathophysiology of CVD and renal disease and appears to place individuals at high risk for cardiovascular (CV) and renal events. Results from many large-scale, long-term clinical trials have demonstrated that RAAS blockade with an angiotensin-converting-enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) can significantly decrease CV and renal morbidity and mortality in a wide range of patients. Some of the clinical benefits derived from use of these agents appears to be independent of their ability to lower blood pressure. The combined use of an ACEI and an ARB for antihypertensive therapy has begun to receive considerable attention. Such an approach may seem counterintuitive, but ACEIs and ARBs have distinct and potentially complementary pharmacologic effects. Results from clinical trials thus far suggest that combination therapy with an ACEI plus an ARB may be a rational choice in patients with chronic activation of the RAAS, including those with heart failure or impaired left ventricular systolic function, diabetes, proteinuria, impaired renal function, recent myocardial infarction, or multiple CV risk factors. Results from ongoing, large-scale, clinical endpoint trials will provide important additional information about the benefits of dual RAAS inhibition in patients at high risk for CV morbidity and mortality.Keywords
This publication has 51 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2007 UpdateCirculation, 2007
- Physiology of Local Renin-Angiotensin SystemsPhysiological Reviews, 2006
- The metabolic syndrome and cardiovascular diseaseAnnals of Medicine, 2006
- ACE Inhibitors and Angiotensin II Receptor Antagonists2005
- Current Status of Hypertension Control Around the WorldClinical and Experimental Hypertension, 2004
- The Renin-Angiotensin System as a Risk Factor and Therapeutic Target for Cardiovascular and Renal DiseaseJournal of the American Society of Nephrology, 2002
- The role of the renin-angiotensin system in the development of cardiovascular diseaseThe American Journal of Cardiology, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991